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Abstract This was a prospective, longitudinal, multicenter,
single-arm controlled trial, using independent core laboratory
validation of MRI results, to establish the effectiveness and
confirm the safety of the VizAblate® System in the treatment
of symptomatic uterine fibroids. The VizAblate System is a
transcervical device that ablates fibroids with radiofrequency
energy, guided by a built-in intrauterine ultrasound probe.
Fifty consecutive women with symptomatic uterine fibroids
received treatment with the VizAblate System. Patients had a
minimum Menstrual Pictogram score of 120, no desire for
fertility, and met additional inclusion and exclusion criteria.
The VizAblate System was inserted transcervically and indi-
vidual fibroids were ablated with radiofrequency energy. An
integrated intrauterine ultrasound probe was used for fibroid
imaging and targeting. Anesthesia was at the discretion of
each investigator. The primary study endpoint was the per-
centage change in perfused fibroid volume, as assessed by
contrast-enhanced MRI at 3 months. Secondary endpoints,
reached at 6 months, included safety, percentage reductions
in the Menstrual Pictogram (MP) score and the Symptom
Severity Score (SSS) subscale of the Uterine Fibroid
Symptom-Quality of Life questionnaire (UFS-QOL), along
with the rate of surgical reintervention for abnormal uterine
bleeding and the mean number of days to return to normal
activity. Additional assessments included the Health-Related
Quality of Life (HRQOL) subscale of the UFS-QOL, medical
reintervention for abnormal uterine bleeding, and procedure
times. Fifty patients were treated, representing 92 fibroids.
Perfused fibroid volumes were reduced at 3 months by an
average of 68.8±27.8 % (P<0.0001; Wilcoxon signed-rank
test). At 6 months, mean MP and SSS scores decreased by
60.8±38.2 and 59.7±30.4 %, respectively; the mean HRQOL
score increased by 263±468 %. There were two serious
adverse events (overnight admissions for abdominal pain
and bradycardia, respectively) and no surgical reinterventions.
These 6-month results suggest that the VizAblate System is
safe and effective in providing relief of abnormal uterine
bleeding associated with fibroids, with appropriate safety
and a low reintervention rate.
Keywords Fibroids . Radiofrequency ablation . VizAblate .
Intrauterine sonography
Introduction
Uterine fibroids are the most prevalent benign uterine tumors
and have an age-specific cumulative incidence in the United
States that is nearly 70 % among white women and greater
than 80% among black women [1]. Despite the availability of
several alternatives to hysterectomy, over 200,000
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hysterectomies are performed annually for fibroids in the
United States [1, 2]. More than 150 years after the first
abdominal hysterectomy for fibroids, there remains a lack of
consensus regarding what constitutes the “gold standard”
treatment for fibroids against which all other treatment options
may be compared [3]. Nonetheless, effective minimally inva-
sive alternatives to hysterectomy exist to accommodate the
growing preference of many women for uterine preservation.
Radiofrequency ablation (RFA) has been used as a fibroid
treatment modality since the early 1990s, with multiple clin-
ical studies confirming its safety and efficacy [4–10]. It has
been shown that radiofrequency ablation produces thermal
fixation and coagulative necrosis within the treated fibroids
[9, 11]. Recent studies have been performed using RFA in
conjunction with simultaneous, real-time sonography to en-
able volumetric ablations, resulting in volume reduction and
symptom improvement [8, 9, 12].
The VizAblate System® (Gynesonics, Redwood City, CA)
is a new medical device that has received CE Mark for
distribution in the European Union. It combines radiofrequen-
cy ablation for the transcervical treatment of uterine fibroids
with intrauterine sonography for real-time imaging [13]. The
Fibroid Ablation Study-EU (FAST-EU) is a study designed to
examine the safety and effectiveness of transcervical radiofre-
quency ablation of uterine fibroids under intrauterine sonog-
raphy guidance with the VizAblate System. This report pre-
sents the 6-month endpoint results of 50 women treated under
the FAST-EU study and is the first report of patient efficacy
data after transcervical radiofrequency ablation of fibroids
under intrauterine sonography guidance.
Materials and methods
Patient selection
This study is a prospective, non-randomized, single-arm, mul-
ticenter controlled trial using independent core laboratory
validation of MRI results. Patients were enrolled from a total
of seven sites in three nations: Mexico (one site), The United
Kingdom (two sites), and The Netherlands (four sites). The
protocol was approved by the Ethics Committees of the re-
spective institutions as well as by the Federal Commission for
Protection against Health Risks (COFEPRIS) in Mexico. All
enrolled patients provided written informed consent for treat-
ment with the VizAblate System prior to enrollment. The
study overview was published on ClinicalTrials.gov (identifi-
er—NCT01226290) and conducted in accordance with
Standard ISO 14155 (Clinical investigation of medical de-
vices for human subjects—Good clinical practice) of the
International Organization for Standardization (ISO), the
Helsinki Declaration of 1975, as revised in 2008, and in
accordance with the ethical standards of applicable national
regulations and institutional research policies and procedures
governing human experimentation.
Women were eligible for inclusion if they were 28 years of
age or older and not pregnant, with regular predictable men-
strual cycles and abnormal uterine bleeding for at least
3 months associated with one to five uterine fibroids measur-
ing between 1 and 5 cm in maximum diameter. Fibroids were
counted in this total if they had an edge within the inner half of
the myometrium; these were termed “target fibroids,” as they
are believed to bemore likely associated with heavymenstrual
bleeding than myomata that are distant from the endometrial
cavity. Target fibroids, which therefore were the only fibroids
to be ablated, consisted of fibroids of FIGO types 1, 2, 3, 4,
and 2–5 (“transmural”). At least one fibroid was required to
i n d e n t t h e e n d ome t r i um , a s d e t e rm i n e d v i a
hysterosonography and/or hysteroscopy and corroborated
via contrast-enhanced MRI. All MRI studies were forwarded
to a core laboratory (MedQIA, 924 Westwood Blvd., Suite
650, Los Angeles, CA 90024, USA) for quality control and
interpretation to reduce variability in the measurements; the
core laboratory also developed standardized imaging proto-
cols for use at the individual study sites, credentialed the sites,
and trained MRI technologists at each study site. A Menstrual
Pictogram score ≥120 was required for inclusion along with a
baseline UFS-QOL SSS score ≥20. The Menstrual Pictogram
is a variant of the Pictorial Blood Loss Assessment Chart
(PBAC) that patients complete to provide a visual assessment
of menstrual blood loss during a single cycle [14, 15]. Unlike
the original PBAC described by Higham and colleagues, the
Menstrual Pictogram includes a greater range of icons
representing different saturations of sanitary products, clots
and losses in a toilet, and also distinguishes different absor-
bency levels of sanitary napkins and tampons [16].
Patients were willing to maintain the use or non-use of
hormonal contraception from 3 months prior to the study
through the 12-month follow-up period. Exclusions included
a desire for future fertility, the presence of one or more type 0
myomata, cervical dysplasia, endometrial hyperplasia, active
pelvic infection, clinically significant adenomyosis (>10 % of
the junctional zone measuring more than 10 mm in thickness
as measured by MRI), and the presence of one or more
treatable fibroids that were significantly calcified (defined as
<75 % fibroid enhancement by volume on contrast-enhanced
MRI). Each patient underwent screening that included
transvaginal sonography, hysteroscopy or hysterosonography,
contrast-enhanced MRI, endometrial biopsy, and a pregnancy
test.
Patients were assigned a unique identification number at
the time that they provided informed consent for study screen-
ing. Patients were considered “enrolled” in the study once
adherence with all inclusion and exclusion criteria had been
verified and documented. All records were de-identified and
only the range of each patient’s age was documented, as per
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clinical trial requirements in The Netherlands. Women were
followed at 7–14 days, 30 days, 3 months, 6 months, and at
12 months post-treatment.
The primary study endpoint was the percentage change in
target fibroid perfused volume as assessed by contrast-
enhanced MRI at baseline and again at 3 months. The patient
success criterion was >30 % reduction in mean target fibroid
perfused volume at 3 months in at least 50 % of patients.
Additional endpoints, reached at 6 months, included safety,
percentage reductions in the Menstrual Pictogram (MP) score
and the Symptom Severity Score (SSS) subscale of the
Uterine Fibroid Symptom-Quality of Life questionnaire
(UFS-QOL), the rate of surgical reintervention for abnormal
uterine bleeding, and the mean number of days to return to
normal activity. While there is no absolute level below which
the SSS would be considered as “within normal limits,” a
population of 29 healthy women without uterine fibroids was
demonstrated by Spies and colleagues to have an average SSS
of 22.5±22.1 [17]. Additional assessments included the
Health-Related Quality of Life (HRQOL) subscale of the
UFS-QOL, medical reintervention for menorrhagia, and pro-
cedure times (as recorded from the start of transvaginal so-
nography to the end of RF ablation). Lower scores on the SSS
subscale are desirable; conversely, higher scores on the
HRQOL subscale are preferable. For the SSS, a 10-point
reduction in the score is generally considered clinically sig-
nificant [17–19].
Statistical analysis
The null hypothesis for this study endpoint is H0: probability
of success <50 % versus the alternative Ha: probability of
success ≥50 %. Thus, the lower bound of the two-sided
95 % confidence interval on the observed probability of
success must be greater than or equal to 50 %. We anticipated
that at least 90 % of the patients would remain in the set of
patients who were not excluded from analysis, and that the
true probability of success for included patients would be
72.0 %. If this is the case, a sample of 40 patients is sufficient
to detect this difference of 22 % in probability of success with
a power of 82 % using a one-group chi-square test with a 0.05
two-sided significance level. Allowing for an expected drop-
out rate of 20% at the 12-month follow-up visit, the minimum
recommended sample size for the initial study protocol was
48. The primary study endpoint success criterion was achieve-
ment of >30 % reduction in mean target fibroid perfused
volume in at least 50 % of patients. The primary endpoint
analysis is performed on a per-fibroid basis, rather than using a
subjective “dominant fibroid” in a given patient who could
have multiple similar fibroids that were ablated.
The Full Analysis dataset includes all patients enrolled
under the protocol who provided a baseline fibroid volume
assessment and received treatment with the VizAblate System.
The Per-Protocol dataset includes all patients enrolled under
the protocol who received treatment with the VizAblate
System and provided both a baseline fibroid volume assess-
ment and a 3-month assessment and/or who received a surgi-
cal reintervention. Patients who received a surgical
reintervention were considered treatment failures. Any pa-
tients with major protocol deviations that were considered to
influence a treatment evaluation were excluded (e.g., preg-
nancy, concomitant procedures, medical reintervention). The
Per-Protocol dataset was used as the primary analysis set for
the primary endpoint analysis.
All statistical analyses were performed with SAS 9.3 (SAS,
Cary, NC). Values were considered significant at the level of
α=0.05. The Wilcoxon signed-rank test was used to test if a
change was significantly different from 0. Missing data were
not imputed for patients included in this Per-Protocol analysis.
Procedure
The VizAblate System consists of a reusable intrauterine
ultrasound (IUUS) probe and a single-use, disposable articu-
lating RF handpiece that are combined into a single treatment
device (Fig. 1). Other integrated components of the VizAblate
System include an RF generator and an ultrasound system
with a custom graphical user interface. This graphical user
interface provides the gynecologist with an image-guided
treatment system that indicates the borders of the thermal
ablation as well as the border beyond which thermal heating
is not present (Fig. 2).
Pregnancy was excluded before the procedure by utilizing
a urine pregnancy test. Anesthesia was chosen by each inves-
tigator in consultation with an anesthesiologist; options in-
cluded general inhalational anesthesia, regional anesthesia,
and conscious sedation with or without paracervical blockade.
Two dispersive electrode pads were placed, one on each
anterior thigh; the dispersive electrodes contain thermocou-
ples positioned at each leading edge for skin temperature
monitoring. Just before insertion of the VizAblate
Handpiece, transvaginal sonography was employed at the
discretion of each investigator to confirm the presence, loca-
tion, and size of each fibroid.
Transvaginal sonography, if desired for fibroid mapping
before insertion of the VizAblate Handpiece, was performed
with a transvaginal ultrasound probe as provided with the
Fig. 1 The VizAblate treatment device
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VizAblate System. After achieving cervical dilatation to
8 mm, the integrated VizAblate Handpiece (containing the
RF electrode array and the intrauterine ultrasound probe) was
inserted transcervically into the uterus. A small volume (gen-
erally 10–15 mL) of hypotonic fluid such as sterile water or
1.5 % glycine was infused through the device for acoustic
coupling. Leiomyomata were then visualized with IUUS and
mapped in a systematic fashion within the uterus.
After articulating the ultrasound probe, the investiga-
tors used the graphical overlay to simulate various abla-
tion widths, angles, and locations of the intended ablation.
In this fashion, before introducing the RF electrodes into a
fibroid, the investigator planned and optimized the abla-
tion. Once the size, angle, and location of the ablation
were established, the investigator advanced a trocar-tipped
introducer into the fibroid under intrauterine ultrasound
visualization. The investigator aligned the graphical over-
lay with the introducer tip and then rotated the VizAblate
Handpiece about the introducer to assess the position of
the Ablation Zone and Thermal Safety Border relative to
the uterine serosa, as displayed on the graphical user
interface, adjusting the size and/or position of the desired
ablation if necessary. Depending on the width of the
ablation, the distance from the Ablation Zone to the uter-
ine serosal margin will vary from 6.0 to 9.5 mm. When
properly positioned, the introducer is located within the
fibroid while the serosa is maintained tangent to or be-
yond the Thermal Safety Border. The investigator then
deployed the electrodes, again rotating to ascertain the
position of the Thermal Safety Border relative to the
serosa. Once the Thermal Safety Border was confirmed
to be within the uterine serosal margin in all adjacent
ultrasound planes, RF energy was used to accomplish
the ablation. Treated fibroids each received one or more
ellipsoidal ablations, ranging from 1 to 4 cm in width and
2–5 cm in length. The number of ablations, along with
their sizes, was at the discretion of the investigator. While
usually only one ablation may sufficiently ablate up to a
5-cm myoma, two smaller ablations might be needed
rather than one larger one, in order to ablate a greater
aggregate volume when a fibroid is close to the serosa or
where there is additional constraint on ablation volume
and position (e.g., the cornu).
The VizAblate System delivers up to 150 W of RF energy
for a preset duration. The RF generator controls energy deliv-
ery to maintain a constant temperature of 105 °C at the needle
Fig. 2 Intrauterine sonogram of a submucosal fibroid with the VizAblate
ablation guides visible (Ablation Zone in red and Thermal Safety Border
in green). The Ablation Zone is a two-dimensional representation of the
average region of tissue ablation for a selected treatment size. Tissue
outside the Thermal Safety Border is at a safe distance from the Ablation
Zone and will be preserved. The serosa is visible as an echogenic border
around the uterus
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electrodes. Upon completion of RF treatment, the needle
electrodes were retracted along with the introducer, the ultra-
sound articulation angle was reset to 0°, and the device was
withdrawn.
Throughout this study, the investigator was asked to
treat fibroids to maximize the ablated volume of each
treated fibroid while maintaining the thermal safety bor-
der within the uterine serosal margin. In doing so, the
investigator determined the best ablation size and loca-
tion for each individual fibroid, and whether one or
more ablations should be performed. The intent was to
ablate all target fibroids (up to the eligibility limit of 5)
present within a given patient. At each center, only a
single physician would perform each procedure in the
interests of consistency and quality.
Results
Patients
Fifty patients were treated in the FAST-EU study at seven
sites. On average, each site treated 7.1 patients ±7.8 (median
5.0; range 1–23), with four centers treating five or more
patients and the remaining three treating one to two patients.
Baseline characteristics for all treated study patients are pro-
vided in Table 1. Anesthesia was provided as noted in Table 2.
The average procedure time (sonography time plus Treatment
Device time) was 38.8±22.5 min (range, 11–95.5 min).
Exclusions from analysis
Two patients (four fibroids) were excluded from a Per-
Protocol analysis of the primary endpoint, perfused fibroid
volume. These two patients were deemed by the core MRI
laboratory to have had unusable imaging for making precise
fibroid measurements at the screening (one patient) and/or 3-
month (both patients) MRI studies. Good faith efforts were
made to obtain MRI studies for these patients that would meet
the strict quality control requirements of the core MRI lab
(MedQIA). As in the end, accurate fibroid contouring mea-
surements could not be obtained in these two patients with any
reasonable degree of reliability; their MRI data did not con-
tribute to the data analysis. There were six (8 %) patients
excluded from one or more of the patient-reported outcomes
(MP, UFS-QOL). Two patients (4 %) underwent an ancillary
fibroid or polyp resection at the time of RF ablation, and as a
result, all of their patient-reported outcomes were excluded
from a Per-Protocol analysis, including their baseline MP and
UFS-QOL results. Three patients (6 %) underwent medical
reintervention (e.g., tranexamic acid) for abnormal uterine
bleeding within 6 months of the ablation procedure, resulting
in exclusion of their patient-reported outcomes at 6 months.
One patient reported a pregnancy at the time of her 6-month
follow-up visit and was thus excluded from the 6-month
analysis. One patient did not turn in her menstrual pictogram
or complete the HRQOL portion of the UFS-QOL. Thus, at
6 months there were 43 patients who were included in the
analysis of MP and UFS-QOL HRQOL and 44 who had data
included in the UFS-QOL SSS analysis.
Mean percentage reduction in perfused and total fibroid
volume
Characteristics of fibroids that were ablated are shown in
Table 3 and ablation results at 3 months for both Per-
Protocol and Full Analysis datasets are provided in Table 4.
Table 1 Baseline patient characteristics
Subjects treated 50
Most frequent age range 41–45 yearsa
Mean menstrual pictogram (MP) score 423±253 (range, 119–1582)
Mean UFS-QOL SSS score 61.7±16.9 (range,
28.1–100.0)
Mean UFS-QOL HRQOL score 34.3±19.0 (range, 0.0–73.3)
Total number of target fibroids identified
on MRI
118
Mean number of target fibroids per patient 2.4±1.7 (range, 1–7)b
Mean diameter of target fibroids 2.9±1.4 cm (range, 1.0–
6.9 cm)
Mean perfused fibroid volume 18.3±20.6 cc (range, 0.3–
77.0 cc)
Mean total (perfused+nonperfused)
fibroid volume
18.8±21.4 cc (range, 0.3–
77.0 cc)
a Subject ages were specified as a range by each site to protect subject
privacy
b Two small additional fibroids, beyond the upper limit of five target
fibroids/patient, were identified on review of one MRI series after
treatment
Table 2 Anesthesia provided to FAST-EU patients
Anesthesia option Number of subjects
General anesthesia alone 15 (30.0 %)
Conscious sedation alone 15 (30.0 %)
Spinal anesthesia alone 8 (16.0 %)
Conscious sedation+epidural anesthesia 8 (16.0 %)
Epidural anesthesia alone 2 (4.0 %)
Paracervical blockade alone 1 (2.0 %)
General anesthesia+epidural anesthesia 1 (2.0 %)
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Fibroids are classified in Table 3 as per the International
Federation of Gynecology and Obstetrics classification sys-
tem [20]. While the Per-Protocol dataset is intended as
the primary analysis source for the primary endpoint,
the Full Analysis dataset is included for comparison. As
noted in the ablation results, radiofrequency ablation
with the VizAblate System was associated with statisti-
cally significant reductions in both total and perfused
fibroid volumes at 3 months. This was true for both the
Full Analysis dataset and Per-Protocol dataset. On a
Per-Protocol basis, half of the fibroids experienced at
least a 77.1 % reduction in perfused volume and at least
a 63.1 % reduction in total volume (76.9 % and
62.5 %, respectively, for the Full Analysis dataset).
Seventy-nine of 88 treated fibroids (89.8 %), in 48
patients for which perfusion data was available at
3 months post-treatment, met or exceeded the primary
study endpoint success criterion (achievement of >30 %
reduction in mean target fibroid perfused volume in at
least 50 % of patients).
Patient-reported outcomes
Patient-reported secondary endpoint data are provided in
Table 5. A 50 % or greater reduction in MP was achieved in
33 of 43 patients (76.7 %) at 6 months. The median reduction
in MP score at 6 months was 70.8 %. Reductions in the MP
and SSS subscale of the UFS-QOL are desired, as are in-
creases in the HRQOL subscale of the UFS-QOL.
As shown in Table 5, the reduction in the transformed SSS
subscale of the UFS-QOL questionnaire at 6 months was
statistically significant, as was the increase in the transformed
HRQOL subscale. Patients experienced nearly a 60 % reduc-
tion in SSS at 6 months.
Device safety
All procedures were successfully completed. The adverse
events attributable to the device or procedure consisted of
dysmenorrhea (six patients), pelvic cramping (four patients),
and abnormal uterine bleeding above the patient’s baseline
(seven patients). The abnormal uterine bleeding above base-
line was seen in six of the seven patients at time points from 3
to 5 months post-ablation and were felt to have been consis-
tent with fibroid sloughing based on their 3-month MRI
studies and clinical presentation. At 6 months, there was a
single bulk expulsion involving a 5.4-cm type 1 myoma at
12 days post-ablation. The patient did not initially mention it
to her treating physician, noting only bulk passage of tissue (as
opposed to gradual sloughing) in response to a physician
query after the fibroid had been noted to have essentially
disappeared on the 3-month MRI study. Given that it is
unlikely that expulsion of a large fibroid could have been
largely asymptomatic, presumably much of the fibroid had
gradually sloughed off to the point where only a small portion
was actually expelled.
Table 4 Reduction in mean perfused and total fibroid volumes at 3 months (Per-Protocol and Full Analysis datasets)
Per-Protocol Full Analysis set
Baseline 3 Months % Reduction
from baseline
P valuea Baseline 3 Months % Reduction
from baseline
P valuea
Number of MRI-evaluable fibroids 89 88 89 89
Number of subjects 49 48 49 49
Perfused fibroid volume (cc) 18.3±20.6
9.5
(0.3–77.0)
5.5±9.2
1.6
(0.0–45.7)
68.8±27.8 %
77.1 %
(−33.3–100 %)
<0.0001 18.3±20.6
9.5
(0.3–77.0)
5.8±9.6
1.6
(0.0–45.7)
68.1±28.6 %
76.9 %
(−33.3–100 %)
<0.0001
Total fibroid volume (cc) 18.8±21.4
9.5
(0.3–77.0)
7.7±11.8
1.9
(0.0–56.3)
55.3±37.2 %
63.1 %
(−85.7–100 %)
<0.0001 18.8±21.4
9.5
(0.3–77.0)
8.0±12.0
1.9
(0.0–56.3)
54.7±37.4 %
62.5 %
(−85.7–100 %)
<0.0001
Data are mean±standard deviation; median; (range)
aWilcoxon signed-rank test, null hypothesis of no change
Table 3 Characteristics of ablated fibroids
Total number of ablated target fibroidsa 92
Mean number of ablated target fibroids per subject 1.8±1.1 (range, 1–5)
Total number of type 0 ablated fibroids 0
Total number of type 1 ablated fibroids 14
Total number of type 2 ablated fibroids 42
Total number of type 3 ablated fibroids 3
Total number of type 4 ablated fibroids 25
Total number of type 2–5 (transmural)
ablated fibroids
8
Mean diameter of ablated fibroids 3.2±1.4 cm (range,
1.1–6.9 cm)
a Includes three fibroids that were ablated in a subject whose MRI data
was not evaluable with regard to precise fibroid measurements
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There were two readmissions within 30 days of the proce-
dure. One patient was admitted overnight on post-procedure
day 9 to receive parenteral antibiotics for a urinary tract
infection and was discharged on the following day. Another
patient, who had no known history of cardiovascular disease
or other medical disorders, developed bradycardia down to
38 bpm shortly after the procedure and was kept overnight in
the hospital for treatment with atropine and observation; the
patient was discharged the next morning in stable condition.
Reintervention
No patient underwent surgical intervention within 6 months of
treatment. Three patients received medical reintervention with
tranexamic acid after presenting at 3 months post-ablation
complaining of persistent or increased abnormal uterine bleed-
ing that was felt to have been secondary to fibroid sloughing
based on the clinical presentation and 3-month MRI findings
of markedly reduced submucous fibroid volume with partial
extrusion into the endometrial cavity.
Pregnancy
There was a single pregnancy reported within the first
6 months after ablation with the VizAblate System. The
patient presented with amenorrhea and a positive pregnancy
test at her 6-month study visit and delivered a liveborn male
infant at term, weighing 3150 g and with Apgar scores of 9
and 9, via elective repeat Cesarean section [21].
Return to normal activity
A total of 47 patients completed a recovery diary relating to
how long it took them to return to their normal activities of
daily life. On average, return to normal activity took 4.4±
3.1 days (median 4.0 days; range 1–14 days).
Discussion
Since the 1990s, there have emerged several modalities to
treat uterine fibroids, including uterine artery embolization
(UAE) and magnetic resonance-guided focused ultrasound
(MRgFUS). Uterine artery embolization is a treatment option,
with a 20–28.4 % failure rate after 5 years [22, 23]. Of note,
UAE is not considered generally applicable for women who
desire future pregnancy, and has been associated with post-
embolization syndrome and, occasionally in older women,
premature ovarian failure [23–28]. Magnetic resonance-
guided focused ultrasound, like radiofrequency ablation
methods, ablates fibroids using energy to generate hyperther-
mic tissue temperatures. However, this modality is not widely
available and requires up to 3 h per treatment.
The VizAblate System uses an incisionless, transcervical
approach to treat symptomatic fibroids, including those that
are not generally amenable to alternative intrauterine treat-
ment approaches such as hysteroscopic resection or
morcellation. Fibroid ablation takes place under real-time
visualization provided by an intrauterine sonography probe
that is integrated within the device. This built-in imaging
removes the need for the physician to coordinate more than
one device and more than one monitor. The graphical user
interface delineates the boundaries of ablation and thermal
spread outside the zone of ablation and enables the operator
to avoid thermal injury to the serosa with its potential for
adhesiogenesis and injury to adjacent viscera. Intrauterine
sonography provides higher-resolution imaging than the more
prevalent transvaginal sonography and has greater precision
and accuracy for the measurement of fibroids near the endo-
metrial cavity [29]. The use of intrauterine sonography has
been demonstrated useful for the imaging of intratubal im-
plants for sterilization after placement [30].
These 6-month results demonstrate that transcervical intra-
uterine sonography-guided radiofrequency ablation of fi-
broids can result in significant reductions in perfused fibroid
volumes and fibroid-associated symptoms. In contrast with
fibroid treatment modalities that often require 1–3 h to accom-
plish, mean treatment times with the VizAblate System were
less than 40 min. Treatment did not require general anesthesia
Table 5 Improvement in patient reported outcomes at 6 months
Baseline 6 Months % Improvement
from baseline
P valuea
MP 48 43 43 <0.0001
418±251 146±144 60.8±38.2 %
361 98 70.8 %
(119–1582) (0–786) (−73.1–100 %)
UFS-QOL SSS 48 44 44 <0.0001
62.1±16.8 23.5±17.8 59.7±30.4 %
60.9 18.8 66.7 %
(28.1–100) (0.0–78.1) (−22.2–100 %)
UFS-QOL
HRQOL
47 43 43 <0.0001
34.5±18.7 82.5±17.8 263±468 %
30.2 86.2 126.0 %
(0.0–73.3) (12.9–100) (−28.6–2800 %)
Data are number of subjects; mean±standard deviation; median; (range)
MP menstrual pictogram, UFS-QOL SSS uterine fibroid symptom and
health-related quality of life symptom severity score subscale, UFS-QOL
HRQOL uterine fibroid symptom and health-related quality of life health-
related quality of life subscale
aWilcoxon signed-rank test, null hypothesis of no change
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in nearly 70 % of patients and recovery time was relatively
brief. The median time for the return to normal activity was
4.0 days, with a mean of 4.4±3.1 days (range, 1–14 days).
This contrasts with laparoscopic radiofrequency ablation of
fibroids, in which the largest published study to date reported
a median time for returning to normal activities of 9 days
(range, 2–60 days) [31].
Transcervical radiofrequency ablation avoids many of the
potential complications associatedwith a laparoscopic or open
procedure for the treatment of fibroids. There are no incisions
and the uterine serosa is not penetrated or coagulated. There is
no entry into the peritoneal cavity, so that intraperitoneal
adhesiogenesis is unlikely. There is no overt risk of ureteral
injury. In contrast to operative hysteroscopy, only a small
quantity of hypotonic fluid is used for acoustic coupling, no
large venous sinuses are exposed, and intrauterine pressure is
not raised to levels above mean arterial pressure, avoiding
significant fluid intravasation. The integral intrauterine sonog-
raphy probe permits visualization of the myometrium and
serosa, permitting a perspective of the myometrium and
intramyometrial pathology that are not readily achievable with
a hysteroscope.
At 6 months, there have been significant reductions in
perfused and total fibroid volumes. Contrast-enhanced MRI
demonstrated a significant reduction in the volume of perfused
fibroid tissue at 3 months. The 3-month time point was select-
ed in order to provide early data on the treatment impact on
fibroid perfusion; it was not assumed prospectively that there
would be a significant impact on total fibroid volume. It was
suspected that reductions in total fibroid volume, caused by
the process of coagulative necrosis, would require a longer
time horizon to be demonstrated on contrast-enhanced MRI.
As with MRgFUS, which is another form of hyperthermic
ablation of uterine fibroids, it is known that sustained symp-
tom relief may be accomplished by ablating as much of the
fibroid volume as possible, although it is not necessary to
ablate 90 % or more of the fibroid to reduce fibroid symptoms
[32]. Nonetheless, there was an average 55.3 % reduction in
total fibroid volume at 3 months, with some fibroids achieving
90–100 % reduction in total volume.
At 6 months, there were statistically significant reductions
in menstrual blood loss, as evidenced by reductions in men-
strual pictogram scores, as well as significant improvements in
both subscales of the UFS-QOL questionnaire. No patients
underwent surgical reintervention within 6 months. Based on
the MP score, bleeding reduction was experienced by 76.7 %
of patients at 6 months. It should be noted that Lukes and
colleagues defined a reduction in menstrual blood loss of
≥36 cc, or a 22 %, reduction, to be the minimum level of
improvement in bleeding that is meaningful to women [33,
34]. Thus, the majority of patients exceeded both standards.
In addition to clinical efficacy, device safety was also
acceptable. No patient required emergency surgery and there
were no unscheduled returns to the operating room. Adverse
events were generally minor and anticipated.
Seven patients experienced abnormal uterine bleeding
above their baseline levels, generally around 3 months post-
treatment. This was felt to be secondary to fibroid sloughing;
MRI studies at 3 months typically revealed extrusion of ab-
lated fibroids into the endometrial cavities with loss of total
fibroid volume. As fibroids undergo coagulative necrosis after
radiofrequency ablation, some patients may experience
sloughing phenomena, particularly if the fibroid is already
partially within the endometrial cavity or, as we speculate,
the fibroid pseudocapsule has been ablated. As all patients are
required to have at least one submucosal fibroid for entrance
into the study, it is perhaps not surprising that 6 of 50 patients
(12 %) had presumptive fibroid sloughing secondary to radio-
frequency ablation. Consistent with reports of patient experi-
ences after MRgFUS, gross expulsion of ablated fibroids was
unusual, occurring in only one patient. Fibroid expulsion is
more common after uterine artery embolization, in contrast to
the experience of thermal ablation methods like MRgFUS and
RF ablation [35–37].
Of the seven centers that treated patients in the FAST-EU
study, half of the centers treated at least five patients. There
was no unusual learning curve; the procedure time varied with
the complexity of the case, with some first cases taking 14.5–
18 min and others involving four to five larger fibroids requir-
ing much longer.
This study has several advantages. Care was taken to
exclude women with suspected anovulation through a
strict inclusion criterion regarding the menstrual history,
along with requiring the presence of at least one fibroid
that indented the endometrial cavity. The latter require-
ment makes it more likely that a patient’s bleeding
symptoms are secondary to fibroids rather than another
etiology. A core MRI facility was used to reduce vari-
ability and bias in MRI imaging quality, interpretation,
and measurements relative to the primary study end-
point. In addition, the use of multiple clinical sites that
include academic medical centers as well as community
hospitals provides a more realistic assessment of the use
of the VizAblate System than would a single site.
Nonetheless, there are some limitations to this study.
The study is a nonrandomized single-arm study and
does not include a sham or another fibroid treatment
for comparison. It was not intended to examine out-
comes for women with fibroids significantly larger than
5.0 cm, with the largest fibroid being 6.9 cm in diam-
eter; additional study will be required to examine abla-
tion outcomes in women with larger fibroid volumes.
Finally, this report includes outcomes through the first
6 months after treatment with the VizAblate System;
longer-term and comparative data are needed, are being
acquired, and will be reported separately.
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Conclusions
Based on the 6-month data from the FAST-EU study, radio-
frequency ablation of uterine fibroids is an effective treatment
modality that preserves the uterus. When performed
transcervically with the VizAblate System, the integrity of
the uterine serosa and abdominal cavity are not violated,
concurrent intrauterine sonography provides a straightforward
method for targeting myomata associated with abnormal uter-
ine bleeding, and general anesthesia is not required.
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